Peak Asset Management LLC Acquires New Shares in Edwards Lifesciences Corporation $EW

Peak Asset Management LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 6,178 shares of the medical research company’s stock, valued at approximately $559,000.

A number of other hedge funds have also added to or reduced their stakes in EW. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences in the first quarter worth about $25,000. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences during the third quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth $26,000. Finally, TrinityBridge Ltd purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $90.53 on Tuesday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm’s 50-day simple moving average is $89.30 and its two-hundred day simple moving average is $84.74. The stock has a market cap of $52.13 billion, a PE ratio of 52.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,570 shares of company stock valued at $2,219,390 over the last three months. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. UBS Group began coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target for the company. Truist Financial boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. BTIG Research increased their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.